112 related articles for article (PubMed ID: 37052970)
1. Correlation of PADI4, GBP1, miR-215, and TMB Expression Levels with Clinical Characteristics and Prognosis of Lung Cancer.
Chen J; Han Y; Zhao Y; Zhu W
Altern Ther Health Med; 2023 Jul; 29(5):238-241. PubMed ID: 37052970
[TBL] [Abstract][Full Text] [Related]
2. Guanylate-binding protein 1 correlates with advanced tumor features, and serves as a prognostic biomarker for worse survival in lung adenocarcinoma patients.
Wan Q; Qu J; Li L; Gao F
J Clin Lab Anal; 2021 Feb; 35(2):e23610. PubMed ID: 33301214
[TBL] [Abstract][Full Text] [Related]
3. Correlation between the risk of lymph node metastasis and the expression of GBP1 in breast cancer patients.
Liu Y; Wu Z; Lin J; Wang Z
Pak J Med Sci; 2024; 40(1Part-I):159-164. PubMed ID: 38196488
[TBL] [Abstract][Full Text] [Related]
4. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer.
Wang SY; Li Y; Jiang YS; Li RZ
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4092-4097. PubMed ID: 29028091
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of microRNA-10b expression in peripheral blood mononuclear cells in evaluating short- and long-term efficacy of chemotherapy for patients with advanced non-small-cell lung cancer.
Yang YL; Wang W; Xu LP
Neoplasma; 2018; 65(4):610-619. PubMed ID: 30064233
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients.
Zhang J; Wang T; Zhang Y; Wang H; Wu Y; Liu K; Pei C
Cancer Biomark; 2018; 21(4):763-768. PubMed ID: 29286916
[TBL] [Abstract][Full Text] [Related]
7. Circ_0058608 contributes to the progression and taxol resistance of non-small cell lung cancer by sponging miR-1299 to upregulate GBP1.
Xuan X; Wang Z; Wang Y
Anticancer Drugs; 2023 Jan; 34(1):103-114. PubMed ID: 36539364
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of serum miR-661 in diagnosis and prognosis of non-small cell lung cancer.
Zhou GH; Yang WH; Sun B
Eur Rev Med Pharmacol Sci; 2017 Dec; 21(24):5696-5701. PubMed ID: 29272005
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of serum miR-25 in non-small-cell lung cancer.
Li J; Yu M; Liu Z; Liu B
Br J Biomed Sci; 2019 Jul; 76(3):111-116. PubMed ID: 30919763
[No Abstract] [Full Text] [Related]
10. Guanylate-Binding Protein 1 as a Potential Predictor of Immunotherapy: A Pan-Cancer Analysis.
Zhao Y; Wu J; Li L; Zhang H; Zhang H; Li J; Zhong H; Lei T; Jin Y; Xu B; Song Q
Front Genet; 2022; 13():820135. PubMed ID: 35222540
[No Abstract] [Full Text] [Related]
11. Clinical value of miR-198-5p in lung squamous cell carcinoma assessed using microarray and RT-qPCR.
Liang YY; Huang JC; Tang RX; Chen WJ; Chen P; Cen WL; Shi K; Gao L; Gao X; Liu AG; Peng XT; Chen G; Huang SN; Fang YY; Gu YY
World J Surg Oncol; 2018 Feb; 16(1):22. PubMed ID: 29394946
[TBL] [Abstract][Full Text] [Related]
12. Low plasma miR-25 expression is a favorite prognosis factor in non-small cell lung cancer.
Zhang YL; Zhang ZL; Zhu XB; Xu L; Lu P; Xu M; Liu WJ; Zhang XY; Yao HM; Ye XW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5251-5259. PubMed ID: 31298376
[TBL] [Abstract][Full Text] [Related]
13. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
[TBL] [Abstract][Full Text] [Related]
14. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
15. Clinical value of miR-135 and miR-20a combined with multi-detector computed tomography in the diagnosis of gastric cancer.
Han W; Bu X; Liu Y; Liu F; Ren Y; Cui Y; Kong S
World J Surg Oncol; 2021 Sep; 19(1):283. PubMed ID: 34537058
[TBL] [Abstract][Full Text] [Related]
16. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
[TBL] [Abstract][Full Text] [Related]
17. [Expression level of miR-199b in human colorectal cancer tissues and its correlation with clinicopathological features and prognosis of patients].
Ma X; Yuan W; Ma J
Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):330-334. PubMed ID: 37078214
[No Abstract] [Full Text] [Related]
18. Downregulation of MicroRNA-330 Correlates with the Radiation Sensitivity and Prognosis of Patients with Brain Metastasis from Lung Cancer.
Jiang LP; Zhu ZT; Zhang Y; He CY
Cell Physiol Biochem; 2017; 42(6):2220-2229. PubMed ID: 28817811
[TBL] [Abstract][Full Text] [Related]
19. The expression and clinical significance of B7-H3 and miR-145 in lung cancer patients with malignant pleural effusion.
Huang L
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(12):6759-6766. PubMed ID: 32633367
[TBL] [Abstract][Full Text] [Related]
20. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis.
Yuxia M; Zhennan T; Wei Z
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2045-50. PubMed ID: 22806310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
